Advertisement
Advertisement
CTOR
Citius Oncology, Inc. Common Stock
0.56
USDSponsored
+0.01
+2.40%
Nov 10, 15:58 UTC -5
Closed
After-Market
0.57
+0.01
+1.48%
Citius Oncology, Inc. Common Stock (CTOR) Earnings
CTOR Earnings Reports
Positive Surprise Ratio
CTOR beat 3 of 7 last estimates.
43%
Next Report
Date of Next Report
Feb 11, 2027
Estimate for Q1 27 (Revenue/ EPS)
$14.56M
/$0.00
Implied change from Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
+269.50%
/-100.00%
Citius Oncology, Inc. Common Stock earnings per share and revenue
On Oct 26, 2026, CTOR reported earnings of -- USD per share (EPS) for Q4 26, -- the estimate of -0.21 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 3.35 million, with a --% difference.
Looking ahead to Q1 27, -- analysts forecast an EPS of 0.00 USD, with revenue projected to reach 14.56 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Citius Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Citius Oncology, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Citius Oncology, Inc. Common Stock's Q4 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Citius Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 11, 2027.
What are the forecasts for Citius Oncology, Inc. Common Stock's next earnings report?
Based on --
analysts, Citius Oncology, Inc. Common Stock is expected to report EPS of -- and revenue of $14.56M for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.